|
gptkbp:instanceOf
|
gptkb:antibiotic
cyclic lipopeptide
|
|
gptkbp:approvedBy
|
gptkb:FDA
2003
|
|
gptkbp:ATCCode
|
J01XX09
|
|
gptkbp:brand
|
gptkb:Cubicin
|
|
gptkbp:CASNumber
|
103060-53-3
|
|
gptkbp:contraindication
|
hypersensitivity to daptomycin
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C72H101N17O26
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
daptomycin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
disrupts bacterial cell membrane
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
1620.67 g/mol
|
|
gptkbp:notEffectiveAgainst
|
gptkb:pneumonia
Gram-negative bacteria
|
|
gptkbp:origin
|
gptkb:Streptomyces_roseosporus
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
92%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
peripheral neuropathy
muscular dystrophy
elevated creatine phosphokinase
eosinophilic pneumonia
|
|
gptkbp:spectrumOfActivity
|
Gram-positive bacteria
|
|
gptkbp:usedFor
|
treatment of complicated skin and skin structure infections
treatment of Staphylococcus aureus bacteremia
treatment of right-sided infective endocarditis
|
|
gptkbp:bfsParent
|
gptkb:Cubicin
|
|
gptkbp:bfsLayer
|
5
|